All In Biotech

Drug Trial Radar · NCT02694822

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Apr 2016

Primary completion

Mar 30, 2022

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Mar 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase 1/2, multicenter study to evaluate the safety, pharmacokinetics, and pharmacodynamics of an anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) human monoclonal antibody (zalifrelimab) in participants with advanced or refractory cancer and in participants who have progressed during treatment with a programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor as their most recent therapy. The phase 1 portion of the study has been completed; it enrolled adult participants with refractory, advanced cancer in a 3+3 dose escalation cohort. The phase 2 portion consisted of 51 participants who progressed during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).

Conditions

  • Advanced Solid Cancers
  • Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

Interventions

  • ZalifrelimabDrug

    An anti-CTLA-4 monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of ZalifrelimabTime frame: Up to 28 days
  2. Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse EventsTime frame: Up to 6 years
  3. Phase 1: Maximum Drug Concentration (Cmax) of ZalifrelimabTime frame: Day 1 of Cycle 1 (21 days/cycle)
  4. Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of ZalifrelimabTime frame: Day 1 of Cycle 1 (21 days/cycle)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • Ochsner Cancer Institute

    New Orleans, Louisiana

  • Atlantic Health System/Morristown Medical Center

    Morristown, New Jersey

  • Levine Cancer Institute

    Charlotte, North Carolina

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Texas Oncology - Austin Midtown

    Austin, Texas

  • Texas Oncology, Tyler Texas

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.